Biofrontera Inc - Warrants (27/10/2026)
BFRIW - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$18.09K
Close$
$-0.25
18278.6% downside
Current Fair Value
18278.6% downsideOvervalued by 18278.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $18,093.00 |
|---|---|
| Enterprise Value | $2.86 Million |
| Earnings per Share | $-1.04 |
| Beta | 0.8 |
| Outstanding Shares | 12,923,710 |
Return
| Return on Equity | -106.87% |
|---|---|
| Return on Assets | -26.45% |
| Return on Invested Capital | -50.93% |
Valuation & Multiples
| P/E Ratio | -1.45 |
|---|---|
| PEG | 1.64 |
| Price to Sales | 0.0 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.06 |
| Enterprise Value to EBIT | -0.42 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 2.62 |
| Debt to Equity | 1.26 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.10
Consensus analyst estimateRevenue Estimate
$9.50 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-0.22
Consensus analyst estimateRevenue Estimate
$8.25 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Biofrontera Inc
82 employees
CEO: Hermann Lübbert
Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company off...